List of Excipients in Branded Drug BRILINTA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	BRILINTA	ticagrelor	0186-0777	DIBASIC CALCIUM PHOSPHATE DIHYDRATE
AstraZeneca Pharmaceuticals LP	BRILINTA	ticagrelor	0186-0777	FERRIC OXIDE YELLOW
AstraZeneca Pharmaceuticals LP	BRILINTA	ticagrelor	0186-0777	HYDROXYPROPYL CELLULOSE
AstraZeneca Pharmaceuticals LP	BRILINTA	ticagrelor	0186-0777	HYPROMELLOSE
AstraZeneca Pharmaceuticals LP	BRILINTA	ticagrelor	0186-0777	MAGNESIUM STEARATE
AstraZeneca Pharmaceuticals LP	BRILINTA	ticagrelor	0186-0777	MANNITOL

Brilinta Excipient Strategy and Commercial Opportunities for Ticagrelor

Last updated: October 16, 2026

Brilinta, AstraZeneca’s ticagrelor product, uses a conventional immediate-release film-coated tablet with a relatively simple excipient system. The commercial opportunity is strongest in generic and specialty formulations that improve manufacturability, dissolution robustness, swallowing, dose flexibility, and supply-chain economics without changing ticagrelor’s established pharmacokinetic profile. AstraZeneca’s core product sales remain exposed to generic entry, while excipient suppliers can target high-volume direct compression, coating, taste-masking, and modified-delivery applications.

What excipients are used in Brilinta tablets?

Brilinta tablets use a standard immediate-release formulation based on a compactible diluent, disintegrant, binder, lubricant, and film-coating system.

Component	Function in the formulation	Commercial relevance
Mannitol	Diluent and mouthfeel modifier	Supports compactibility and acceptable oral texture
Dibasic calcium phosphate	Diluent and compression aid	Improves tablet hardness and dimensional control
Sodium starch glycolate	Superdisintegrant	Supports rapid tablet breakup
Hydroxypropyl cellulose	Binder	Improves granulation and tablet mechanical strength
Magnesium stearate	Lubricant	Reduces ejection force and tooling adhesion
Hypromellose	Film former	Provides tablet coating and surface protection
Titanium dioxide	Opacifier and pigment	Controls appearance and light protection
Talc	Anti-tacking and coating aid	Improves coating performance
Ferric oxide pigments	Colorant	Differentiates 60 mg and 90 mg strengths

The U.S. prescribing information identifies these inactive ingredients for the 60 mg and 90 mg immediate-release tablets. The tablets differ in color and strength marking, but the core excipient architecture is substantially similar.[1]

This formulation is commercially important because it uses familiar, globally available excipients rather than a proprietary delivery platform. A generic manufacturer can pursue a conventional immediate-release tablet while optimizing particle size, grade, blending order, granulation method, compression force, and coating parameters.

How does Brilinta’s formulation affect generic development?

Ticagrelor generic development is likely to focus on dissolution control and bioequivalence rather than exact excipient duplication. An ANDA applicant generally must demonstrate pharmaceutical equivalence and bioequivalence, but it does not necessarily need to reproduce every inactive ingredient in the reference product.[2]

The practical constraints are more specific:

1. The formulation must provide rapid and reproducible release.
2. Tablet hardness cannot delay disintegration.
3. Magnesium stearate concentration and blending time must be controlled because over-lubrication can reduce wetting and dissolution.
4. Calcium phosphate and mannitol grades can materially affect powder flow and compression.
5. Coating pigments must maintain strength differentiation and visual consistency.
6. The product must remain suitable for patients who cannot swallow tablets.

Ticagrelor is a low-solubility active pharmaceutical ingredient relative to highly water-soluble antiplatelet drugs. Formulation developers therefore have an incentive to improve wetting and dissolution without creating a new pharmacokinetic profile. Particle-size reduction, wetting agents, optimized disintegrant systems, and amorphous or partially amorphous drug dispersions are possible approaches. Each option increases development and stability risk compared with a conventional tablet.

What excipient strategies can improve ticagrelor performance?

Direct-compression optimization

The simplest strategy is to preserve the reference product’s immediate-release profile while improving manufacturing efficiency. Mannitol and dibasic calcium phosphate can be selected in grades that support direct compression, lower friability, and better flow.

Potential opportunities include:

• Spray-dried mannitol for improved flow and compactibility
• Co-processed mannitol-cellulose or mannitol-starch systems
• Low-moisture excipient grades for improved ticagrelor stability
• Fine-particle dibasic calcium phosphate for improved content uniformity
• Lower-level, high-efficiency superdisintegrants
• Magnesium stearate alternatives that reduce hydrophobicity

The main commercial value is lower tablet weight, higher press speed, and lower rejection rates. Because ticagrelor tablets contain a relatively potent active ingredient, content uniformity is manageable, but small batch-to-batch changes in powder segregation can still affect uniformity.

Dissolution enhancement

Dissolution enhancement is the higher-value technical opportunity. Candidate technologies include:

• Micronized or nanomilled ticagrelor
• Surfactant-assisted wetting
• Amorphous solid dispersions
• Spray-dried polymer dispersions
• Liquisolid systems
• Cyclodextrin complexes
• Porous carrier systems
• Supersaturating formulations with precipitation inhibitors

A conventional immediate-release generic is likely to have the lowest regulatory risk. A dissolution-enhanced product may have a stronger commercial position but can trigger additional clinical, stability, or regulatory work if exposure changes.

The preferred excipient strategy is usually a modest improvement in wetting and disintegration rather than a high-loading amorphous dispersion. This reduces the risk of recrystallization, altered absorption, and scale-up failures.

Taste masking and swallowability

Brilinta tablets are intended for oral administration, but the prescribing information permits crushing and dispersing the tablets in water for patients unable to swallow them. The dispersion may be administered orally or through a nasogastric tube, subject to label instructions.[1]

This creates a commercial opening for:

• Orodispersible tablets
• Taste-masked granules
• Sprinkle formulations
• Oral powders for suspension
• Low-volume aqueous dispersions
• Pediatric or dysphagia-oriented dosage forms

Taste masking is technically relevant because ticagrelor products may produce bitterness when crushed or dispersed. Polymer coatings, ion-exchange resins, lipid barriers, and multiparticulate systems can reduce palatability. The formulation must still release ticagrelor rapidly after administration and remain compatible with enteral feeding tubes.

Color and product identification

Brilinta uses differentiated tablet colors for the 60 mg and 90 mg strengths. Generic manufacturers can use alternative pigments, but the product must comply with labeling, pharmaceutical equivalence, and medication-error controls.

Iron oxide pigments are inexpensive and widely available. The commercial opportunity is less about premium pricing than about supply continuity, color matching, and avoiding pigment variability across manufacturing sites. A dual-source strategy for ferric oxide, titanium dioxide, hypromellose, and talc can reduce production interruptions.

What FDA regulatory requirements apply to ticagrelor excipients?

The reference product is FDA-approved under NDA 022433. Brilinta received U.S. approval in 2011 for reducing cardiovascular death, myocardial infarction, and stroke in acute coronary syndrome and for related secondary-prevention indications. The 60 mg dose is used for certain long-term secondary-prevention settings, while the 90 mg dose is used during the first year after acute coronary syndrome.[1]

A ticagrelor generic applicant must address:

• Pharmaceutical equivalence
• Immediate-release dissolution
• Relative bioavailability or bioequivalence
• Inactive-ingredient safety
• Manufacturing process validation
• Tablet identification and strength differentiation
• Stability under ICH conditions
• Compatibility with crushing or dispersion where relevant to labeling

The FDA Inactive Ingredient Database can support excipient selection, particularly for applicants seeking a route that avoids novel excipient toxicology concerns.[3] An excipient used at a higher level, in a different route, or in a different dosage form may require additional justification.

The principal regulatory risk is not the presence of a familiar excipient. It is the interaction between excipient grade, manufacturing process, dissolution, and systemic exposure.

When does Brilinta lose exclusivity?

Brilinta’s five-year new chemical entity exclusivity expired in 2016, based on its 2011 U.S. approval. Any remaining market protection depends on patent listings, pediatric exclusivity, regulatory exclusivity associated with later approvals, and litigation outcomes rather than the original NCE period.[1,4]

Milestone	Status or timing
U.S. NDA approval	2011
NCE exclusivity	Expired in 2016
60 mg and 90 mg commercial strengths	Established reference-product strengths
Generic pathway	ANDA, subject to applicable Orange Book patents and certifications
Key market exposure	Acute coronary syndrome and secondary prevention
Primary formulation type	Immediate-release film-coated tablet

Patent expiration dates must be assessed against the current FDA Orange Book and individual court dockets. A generic applicant can file under Paragraph III or Paragraph IV depending on the listed patent landscape and the applicant’s non-infringement or invalidity position.[4]

What is the Orange Book status of Brilinta?

Brilinta is listed in the FDA Orange Book under AstraZeneca’s NDA. The Orange Book provides the operative record for listed patents, use codes, and certifications associated with approved generic applications.[4]

For commercial planning, the important distinction is between:

• Compound patents covering ticagrelor itself
• Formulation patents covering tablet composition or dosage form
• Method-of-use patents covering cardiovascular indications or dosing regimens
• Manufacturing patents covering intermediates or processes
• Regulatory exclusivity that may not appear as a conventional patent barrier

A Paragraph IV filing can trigger patent litigation and a potential 30-month stay of final ANDA approval under the Hatch-Waxman framework. The commercial launch date then depends on patent expiration, settlement terms, court decisions, or at-risk launch exposure.[5]

An excipient strategy can reduce formulation patent risk if it uses a materially different composition and process. It does not eliminate compound or method-of-use risk. Freedom-to-operate analysis must cover the finished tablet, excipient ratios, coating system, process steps, and proposed labeling.

What formulation patents could protect ticagrelor products?

Formulation patent claims may focus on:

• Specific ticagrelor-to-excipient ratios
• Particle-size distributions
• Amorphous or crystalline forms
• Solid dispersions
• Dissolution specifications
• Granulation methods
• Coated multiparticulates
• Oral suspension or pediatric dosage forms
• Administration through enteral feeding tubes
• Stabilization against moisture or recrystallization

A conventional generic that uses mannitol, calcium phosphate, sodium starch glycolate, hydroxypropyl cellulose, and magnesium stearate may be commercially efficient but could require careful claim mapping. A differentiated formulation using a co-processed excipient or alternative disintegration system may reduce overlap with composition claims, but it can introduce its own patentable subject matter.

Excipient suppliers can participate through platform patents covering co-processed carriers, taste-masking systems, dispersion technologies, and film-coating compositions. The strongest commercial position usually combines a functional performance advantage with regulatory familiarity and a scalable supply chain.

Which companies are positioned to challenge or supply Brilinta generics?

The likely competitive field includes large generic manufacturers, specialty generic companies, contract development and manufacturing organizations, and excipient suppliers. The most credible entrants are those with:

• Existing antiplatelet or cardiovascular product portfolios
• ANDA infrastructure
• Internal analytical capabilities
• Access to high-quality ticagrelor API
• Experience with low-solubility immediate-release products
• Capacity for multiple strengths and global registrations

Excipient suppliers can target generic developers through formulation kits containing direct-compression mannitol, calcium phosphate, high-efficiency disintegrants, lubricants, and ready-to-use film coatings. The value proposition is shorter formulation development time, lower scale-up risk, and more predictable dissolution.

A supplier with only commodity excipients will face price pressure. A supplier with dissolution data, tabletability data, and regulatory documentation can command better margins.

What commercial opportunities exist beyond standard generic tablets?

Value-added generics

The strongest opportunities are products that solve practical administration problems:

• 60 mg and 90 mg tablets with improved swallowability
• Taste-masked crushed-tablet alternatives
• Enteral-tube-compatible dosage forms
• Lower-weight tablets
• Moisture-stable products for global markets
• Packaging optimized for adherence and dose differentiation

Pediatric and geriatric formulations

Ticagrelor’s approved use is concentrated in adults, but geriatric patients and patients with dysphagia create an administration opportunity. A pediatric formulation would require a separate regulatory and clinical strategy. The excipient burden would include palatability, age-appropriate safety, dosing flexibility, and preservative selection.

Regional manufacturing

A simplified tablet architecture supports regional production in North America, Europe, India, China, Latin America, and emerging markets. Local excipient qualification can reduce freight cost, but substitutions must be supported by comparative dissolution, process validation, and stability data.

Contract development services

CDMOs can offer ticagrelor development packages covering:

• Preformulation
• Excipient screening
• Roller compaction or wet granulation
• Direct-compression feasibility
• Comparative dissolution
• Pilot-scale bioequivalence batches
• Film-coating optimization
• Stability studies
• Scale-up and technology transfer

This is a practical opportunity because the formulation does not require a complex sterile process or biologic manufacturing platform.

How strong is Brilinta’s formulation patent estate?

The formulation estate is likely less difficult to design around than a biologic delivery platform because the reference product uses familiar immediate-release excipients. The principal barriers are regulatory timing, API sourcing, bioequivalence, and any surviving patent claims covering ticagrelor composition, formulation, or use.

A strong freedom-to-operate position would require:

1. A claim chart against every current Orange Book patent.
2. Separate analysis of 60 mg and 90 mg products.
3. Review of polymorph, particle-size, and solid-state claims.
4. Evaluation of crushed-tablet and enteral-administration claims.
5. Review of pending applications and non-Orange Book process patents.
6. Assessment of Paragraph IV litigation and settlement restrictions.

Excipient substitution can improve design-around potential, but it is not a substitute for a full patent analysis.

What revenue exposure exists for AstraZeneca and generic entrants?

Brilinta has been a material AstraZeneca cardiovascular product, with annual global sales in the approximate $1.5 billion range in recent reporting years.[6] The exposure is concentrated in high-volume cardiovascular markets where generic substitution can be rapid after legal barriers fall.

Generic entrants face a different economic profile:

• High initial price erosion after multiple approvals
• Potential launch-value premium for the first approved applicant
• Lower API and excipient costs than branded manufacturing
• Significant litigation and regulatory expenses
• Volume potential from two strengths and broad cardiovascular use
• Margin pressure from pharmacy-benefit and hospital purchasing channels

Excipient suppliers benefit before full generic price erosion because development programs purchase formulation materials, analytical standards, pilot batches, and validation quantities. The recurring opportunity depends on winning commercial supply contracts after approval.

What generic launch scenarios exist for Brilinta?

Scenario	Market effect	Excipient implication
Single first generic	Limited early competition and stronger pricing	Premium for reliable, scalable formulation supply
Several simultaneous generics	Rapid price erosion	Cost and supply continuity become decisive
Paragraph IV settlement	Delayed or licensed entry	Longer development window for formulation optimization
At-risk launch	Immediate litigation exposure	Need for non-infringing formulation and process design
Value-added launch	Differentiated administration or stability	Potentially better margins than commodity tablets
Regional launch	Limited geographic substitution	Local excipient qualification gains importance

The most defensible commercial strategy is a conventional ANDA product supported by a differentiated development package, with a separate value-added formulation reserved for markets where generic price erosion is less severe.

Key Takeaways

• Brilinta uses a conventional immediate-release tablet with mannitol, dibasic calcium phosphate, sodium starch glycolate, hydroxypropyl cellulose, magnesium stearate, and a hypromellose-based coating system.
• The primary technical opportunity is dissolution and manufacturability optimization, not a complex delivery platform.
• Direct-compression excipient systems offer the lowest regulatory and scale-up risk.
• Taste masking, oral dispersion, and enteral-tube-compatible products create higher-value opportunities.
• Ticagrelor’s NCE exclusivity expired in 2016; current entry timing depends on Orange Book patents, litigation, settlements, and applicable regulatory exclusivity.
• Excipient substitution can support formulation design-around but does not resolve compound or method-of-use patent risk.
• Brilinta’s roughly $1.5 billion annual sales base creates meaningful generic and excipient-supply opportunity, with rapid price erosion likely after broad entry.
• Suppliers with formulation data and regulatory documentation are better positioned than commodity-only excipient vendors.

FAQs

Can Brilinta tablets be formulated without mannitol?

Yes. Mannitol is not inherently required for ticagrelor, but removing it changes tabletability, dissolution, mouthfeel, and weight. The alternative diluent system must support bioequivalence and stability.

Is an amorphous ticagrelor formulation commercially attractive?

It can improve apparent dissolution, but recrystallization, physical stability, and exposure changes create additional development risk. It is more attractive for a value-added product than for the lowest-cost ANDA strategy.

Which excipients are most important for ticagrelor dissolution?

The disintegrant, lubricant, wetting characteristics of the diluent system, particle size of ticagrelor, and compression force have the greatest practical impact. Sodium starch glycolate and magnesium stearate levels require particular process control.

Can a generic manufacturer copy Brilinta’s inactive ingredients?

A generic manufacturer may use the same inactive ingredients, but exact duplication is not always required. The formulation must meet pharmaceutical equivalence, bioequivalence, safety, quality, and labeling requirements.

Does a new oral suspension of ticagrelor avoid Brilinta patent risk?

No. A new dosage form may avoid some tablet composition claims, but compound, use, solid-state, manufacturing, and formulation patents can still apply. The product requires a separate patent and regulatory assessment.

References

1. U.S. Food and Drug Administration. (2024). Brilinta (ticagrelor) prescribing information. AstraZeneca Pharmaceuticals LP.

2. U.S. Food and Drug Administration. (2023). Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA: Guidance for industry. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

6. AstraZeneca PLC. (2024). Annual report and Form 20-F. London: AstraZeneca.